Instil Bio Inc. (NASDAQ:TIL) — Market Cap & Net Worth
Market Cap & Net Worth: Instil Bio Inc. (TIL)
Instil Bio Inc. (NASDAQ:TIL) has a market capitalization of $53.58 Million ($53.58 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21633 globally and #4601 in its home market, demonstrating a -3.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Instil Bio Inc.'s stock price $7.90 by its total outstanding shares 6781976 (6.78 Million). Analyse TIL cash generation efficiency to see how efficiently the company converts income to cash.
Instil Bio Inc. Market Cap History: 2021 to 2026
Instil Bio Inc.'s market capitalization history from 2021 to 2026. Data shows change from $2.32 Billion to $53.58 Million (-56.00% CAGR).
Index Memberships
Instil Bio Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #622 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2083 of 3165 |
Weight: Instil Bio Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Instil Bio Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Instil Bio Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TIL by Market Capitalization
Companies near Instil Bio Inc. in the global market cap rankings as of May 4, 2026.
Key companies related to Instil Bio Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Instil Bio Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, Instil Bio Inc.'s market cap moved from $2.32 Billion to $ 53.58 Million, with a yearly change of -56.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $53.58 Million | -28.18% |
| 2025 | $74.60 Million | -42.38% |
| 2024 | $129.47 Million | +150.52% |
| 2023 | $51.68 Million | -39.52% |
| 2022 | $85.45 Million | -96.32% |
| 2021 | $2.32 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Instil Bio Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.58 Million USD |
| MoneyControl | $53.58 Million USD |
| MarketWatch | $53.58 Million USD |
| marketcap.company | $53.58 Million USD |
| Reuters | $53.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Instil Bio Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as … Read more